Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution

Affiliations

¹ Box 356175, Center for Interstitial Lung Diseases, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: graghu@uw.edu.

Comment

Ganesh Raghu. Lancet Respir Med. 2016 Sep.

. 2016 Sep;4(9):e46-e47.

doi: 10.1016/S2213-2600(16)30234-X.

¹ Box 356175, Center for Interstitial Lung Diseases, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: graghu@uw.edu.

No abstract available

Comment in

Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply.
Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJF, Costabel U. Kreuter M, et al. Lancet Respir Med. 2016 Sep;4(9):e48. doi: 10.1016/S2213-2600(16)30235-1. Lancet Respir Med. 2016. PMID: 27599251 No abstract available.

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U. Kreuter M, et al. Lancet Respir Med. 2016 May;4(5):381-9. doi: 10.1016/S2213-2600(16)00067-9. Epub 2016 Mar 31. Lancet Respir Med. 2016. PMID: 27050871

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U. Kreuter M, et al. Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12. Respiration. 2017. PMID: 28399537 Free PMC article.
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
Raghu G. Raghu G. Eur Respir Rev. 2017 Sep 27;26(145):170071. doi: 10.1183/16000617.0071-2017. Print 2017 Sep 30. Eur Respir Rev. 2017. PMID: 28954769 Free PMC article. Review.
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.
Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Costabel U, et al. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0. Respir Res. 2018. PMID: 30176872 Free PMC article. Clinical Trial.
Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study.
Morgan AD, Massen GM, Whittaker HR, Stewart I, Jenkins G, George PM, Quint JK. Morgan AD, et al. Pneumonia (Nathan). 2025 Jan 25;17(1):2. doi: 10.1186/s41479-024-00155-7. Pneumonia (Nathan). 2025. PMID: 39856755 Free PMC article.